Firstly, antibodies that are capable of passing the blood brain barrier (BBB) (that is increasingly permeable with aging and in AD [23], [24]) and then enter neurons, modulating phosphorylation and/or degradation of tau directly. This evidence concerns the gene MAPT and Alzheimer disease.